- cafead Dec 04, 2022 at 01:22: PM
via While Eisai’s lecanemab stole the headlines at this year’s CTAD meeting there were also early data on an intriguing gene therapy being developed by the private group Lexeo.
The company is not targeting amyloid, as such, but rather a genetic risk factor for the disease, namely ApoE4. Lexeo only presented safety and biomarker results from a handful of patients, so it is impossible to gauge its chances; even if the group prevails, eventual uptake of its therapy would depend on the availability of ApoE4 testing.
article source
The company is not targeting amyloid, as such, but rather a genetic risk factor for the disease, namely ApoE4. Lexeo only presented safety and biomarker results from a handful of patients, so it is impossible to gauge its chances; even if the group prevails, eventual uptake of its therapy would depend on the availability of ApoE4 testing.
article source